Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Efficacy of double autologous stem cell transplantation in multiple myeloma - A prospective single center experience in 71 patients (CROSBI ID 536630)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Nemet, Damir ; Sertić, Dubravka ; Mrsić, Mirando ; Bojanić, Ines ; Batinić, Drago ; Duraković, Nadira ; Golubić Ćepulić, Branka ; Serventi Seiwerth, Ranka ; Radman, Ivo ; Aurer, Igor et al. Efficacy of double autologous stem cell transplantation in multiple myeloma - A prospective single center experience in 71 patients // Haematologica. 2007. str. 256-256

Podaci o odgovornosti

Nemet, Damir ; Sertić, Dubravka ; Mrsić, Mirando ; Bojanić, Ines ; Batinić, Drago ; Duraković, Nadira ; Golubić Ćepulić, Branka ; Serventi Seiwerth, Ranka ; Radman, Ivo ; Aurer, Igor ; Zupančić Šalek, Silva ; Labar, Boris.

engleski

Efficacy of double autologous stem cell transplantation in multiple myeloma - A prospective single center experience in 71 patients

Background: Clinical trials so far have shown that high-dose therapy and ASCT) improves response rates, disease-free survival (DSF), and overall survival (OS) in symptomatic patients with multiple myeloma (MM) younger than 65 years. Recent studies indicate survival benefit for MM patients treated with double ASCT as compared to single transplant. We conducted a prospective trial of two successive ASCT in patients with advanced stage MM. The aim of the study was to evaluate feasibility, efficacy, and toxicity of this treatment approach. Patients: From December 1994 to November 2005 71 consecutive, previously untreated patients with MM stage II or III were included in the program of double HSCT. Patients who were pre-treated with melphalan or were treated with more than two chemotherapy regimens before ASCT were not included in the analysis. Median age of patients was 53 years (range 30-65 years), M/F ratio 39/32. Methods: Patients received induction with 3 to 10 cycles of VAD, few of them also other salvage regimen due to refractoriness to VAD. After achieving PR they proceed to mobilization procedure with cyclophosphamide 4 g/m2 and G-CSF. Conditioning regimen for majority of patients consisted of melphalan 200 mg/m2, 24 patients received melphalan 140 mg/m2 and fractionated TBI 800 cGy prior to second transplant. Results: Sixty three patients (89%) actually received double transplant. Eight patients (11%) received only one transplant due to progression of the disease (1 pt), no enough stem cells for second transplant (3 pts), low performance status (3 pts) or refusal of second transplant (1 pt). A complete response was achieved in 47 patients (66%). With the median follow up of 45 months (range 10 to 150 months) 36 (51%) patients were alive in CR or VGPR, 19 (26%) were alive with disease, and 14 (20%) patients died from relapse. Only two patients died from transplant related complication (3%). Survival was calculated from the time of diagnosis. Probability of EFS at 7 years after the diagnosis was 35%. Median progression-free survival was 60 months. Probability of OS at seven years was 56% and the median survival was not reached. Multivariate analysis of parameters prior to transplantation identified age, disease stage at dg II vs III, preASCT response status CR/PR vs other, hemoglobin < 80 g/L, beta2 M > 2, 5 mg/L, and albumin < normal value as factors associated with OS and EFS after transplantation. Conclusion: Double ASCT is feasible in majority of patients, achieve a favorable EFS and OS and is associated with low TRM rate. The toxicity is low even in older patient population, not higher than with single transplant. For all patients with stage II or III MM double AHSCT should be planned from the time of diagnosis.

utologous stem cell transplantation ; multiple myeloma

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

256-256.

2007.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Haematologica

0390-6078

Podaci o skupu

12th Congress of the European Hematology Association

poster

07.06.2007-10.06.2007

Beč, Austrija

Povezanost rada

Kliničke medicinske znanosti

Indeksiranost